C. Eric Schwartz, Ph.D.
Vice President, Drug Discovery
Eric Schwartz brings more than two decades of experience in drug discovery and development to Cedilla. He started his industry career in 1990 at Eisai Research Institute and later moved to positions of increasing responsibility at UCB Pharma, Biogen Idec, and Resolvyx Pharmaceuticals. In 2011 he joined Avila Therapeutics, which was acquired the following year by Celgene, where he served as executive director of chemistry until joining the team at Cedilla in May 2018. Eric received his B.S. degree from Ohio State University, completed his Ph.D. with Ed Vedejs at the University of Wisconsin-Madison, and followed that with a post-doctoral stint at the University of Pittsburgh in Dennis Curran’s group.